Thorac cardiovasc Surg 2018; 66(01): 053-062
DOI: 10.1055/s-0037-1608761
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Regenerative Medicine/Cardiac Cell Therapy: Pluripotent Stem Cells

Ana G. Duran
1  Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapies, Berlin, Germany
,
Olivia Reidell
1  Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapies, Berlin, Germany
,
Harald Stachelscheid
1  Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapies, Berlin, Germany
2  Berlin Institute of Health, Berlin, Germany
,
Kristin Klose
1  Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapies, Berlin, Germany
,
Manfred Gossen
1  Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapies, Berlin, Germany
,
Volkmar Falk
3  DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany
4  Deutsches Herzzentrum Berlin, Berlin, Germany
,
Wilhelm Röll
5  Klinik für Herzchirurgie, Universitätsklinikum Bonn, Bonn, Nordrhein-Westfalen Germany
,
Christof Stamm
1  Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapies, Berlin, Germany
3  DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany
4  Deutsches Herzzentrum Berlin, Berlin, Germany
› Author Affiliations
Further Information

Publication History

27 June 2017

12 October 2017

Publication Date:
07 December 2017 (eFirst)

Abstract

For more than 20 years, tremendous efforts have been made to develop cell-based therapies for treatment of heart failure. However, the results of clinical trials using somatic, nonpluripotent stem or progenitor cells have been largely disappointing in both cardiology and cardiac surgery scenarios. Surgical groups were among the pioneers of experimental and clinical myocyte transplantation (“cellular cardiomyoplasty”), but little translational progress was made prior to the development of cellular reprogramming for creation of induced pluripotent stem cells (iPSC). Ever since, protocols have been developed which allow for the derivation of large numbers of autologous cardiomyocytes (CMs) from patient-specific iPSC, moving translational research closer toward clinical pilot trials. However, compared with somatic cell therapy, the technology required for safe and efficacious pluripotent stem cell (PSC)-based therapies is extremely complex and requires tremendous resources and close interactions between basic scientists and clinicians. This review summarizes PSC sources, strategies to derive CMs, current cardiac tissue engineering approaches, concerns regarding immunogenicity and cellular maturity, and highlights the contributions made by surgical groups.